Orris

Management of patents 45 year female with family history of cancer likely lynch syndrome Patient having right breast lump T3N0M0

Reading File
Finding Sources
Finding Sources
Searching PubMed

breast cancer AND neoadjuvant therapy

Searching the Web

NCI PDQ breast cancer treatment neoadjuvant systemic therapy stage IIB genetic testing Lynch syndrome

Finding Sources
Finding Sources
Finding Sources
Reading Web Page

https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

Working diagnosis: a biopsy-proven invasive right breast cancer with cT3 cN0 cM0 is anatomically stage IIB. T3 means the invasive tumor is more than 5 cm. The final prognostic stage and treatment plan also depend on grade, ER, PR, HER2 status, and response to any preoperative treatment. The NCI staging table lists T3 N0 M0 as stage IIB.
This requires prompt management by a breast multidisciplinary team: breast surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, and genetic counselor.

1. Confirm diagnosis and complete assessment

  1. Triple assessment
    • Clinical examination of both breasts and axillae.
    • Bilateral diagnostic mammography and targeted breast/axillary ultrasound.
    • Core-needle biopsy of the breast lesion.
    • Report histology, grade, ER, PR, HER2, and Ki-67 where used.
    • Ultrasound-guided core biopsy of any suspicious axillary node, with clip placement if positive.
  2. Define local and distant extent
    • Breast MRI if mammography/ultrasound does not define extent adequately, there is suspected multifocal disease, dense breasts, or breast-conserving surgery is being considered.
    • Since this is T3 disease, obtain metastatic staging, typically contrast CT chest/abdomen/pelvis plus bone scan, or PET-CT where appropriate. Bailey and Love recommends metastatic assessment for T3/T4 or N2/N3 disease.
    • Baseline CBC, renal/liver function, alkaline phosphatase.
    • If HER2-positive therapy is possible, obtain baseline cardiac function assessment, usually echocardiography.
  3. Do not rely on clinical N0 alone
    • A clinically negative axilla may still contain microscopic nodal disease. Sentinel-node staging is usually required at definitive surgery.

2. Preoperative systemic therapy is generally preferred

For a 45-year-old with a T3 tumor, neoadjuvant systemic therapy is often preferred. It can shrink the tumor, increase the chance of breast conservation, test tumor response, and guide postoperative therapy. The exact regimen is determined by receptor subtype.
Tumor subtypeUsual preoperative approach
Triple-negative breast cancerNeoadjuvant chemotherapy, commonly with pembrolizumab in eligible stage II-III cases, followed by surgery. Residual disease may alter postoperative systemic treatment.
HER2-positiveNeoadjuvant chemotherapy with HER2-directed treatment, usually trastuzumab-based and often dual HER2 blockade in stage II disease. If residual invasive disease remains, postoperative treatment may be escalated.
ER/PR-positive, HER2-negativeNeoadjuvant chemotherapy if clinically high risk, large/high-grade tumor, or to facilitate breast conservation. In selected strongly hormone-positive tumors, neoadjuvant endocrine therapy can be considered, more commonly in postmenopausal patients.
The current textbook guidance supports neoadjuvant checkpoint inhibitor plus chemotherapy in higher-risk early triple-negative cancer and neoadjuvant anti-HER2 therapy plus chemotherapy in HER2-positive disease. A recent systematic review also supports the evolving evidence base for neoadjuvant immunotherapy in breast cancer, though it is relevant specifically to appropriate subtypes, not every breast cancer (PMID 40213551).

3. Surgery after response assessment

After neoadjuvant treatment, reassess clinically and with imaging.
  • Breast-conserving surgery can be offered if a clear-margin excision is feasible with acceptable cosmetic outcome.
  • Otherwise, perform mastectomy. Immediate or delayed reconstruction should be discussed before surgery.
  • For an initially cN0 axilla, sentinel lymph-node biopsy is generally used at surgery.
  • Axillary dissection is reserved for selected patients with proven or significant residual nodal disease, based on contemporary local protocols and radiation planning.
Lumpectomy followed by radiotherapy provides survival equivalent to mastectomy for appropriately selected stage I-II disease, but this patient’s large tumor may or may not become suitable for conservation after systemic therapy.

4. Radiotherapy and postoperative systemic treatment

  • After breast-conserving surgery: whole-breast radiotherapy is standard.
  • After mastectomy: T3 disease is a major factor favoring post-mastectomy chest-wall radiotherapy, with regional-node irradiation decided from pathology, pretreatment stage, and response to neoadjuvant therapy.
  • Endocrine therapy: indicated if ER and/or PR positive. At age 45, this may involve tamoxifen with or without ovarian suppression, or ovarian suppression plus an aromatase inhibitor, according to recurrence risk and menopausal status.
  • Complete HER2-directed therapy when HER2-positive, typically for a total planned duration of one year in standard pathways.
  • For triple-negative disease, postoperative treatment is guided by pembrolizumab use and whether residual disease is present.

5. Family history and suspected Lynch syndrome

Do not assume that the breast cancer is caused by Lynch syndrome. Lynch syndrome classically increases risk of colorectal, endometrial, ovarian, upper urinary tract, gastric, small-bowel, pancreatic, and some other cancers. The breast cancer association is not sufficiently certain to change breast surgery solely on the basis of suspected Lynch syndrome. The NCI genetics summary advises breast screening in Lynch syndrome based on family history because definitive breast-risk estimates are lacking.

Genetic actions now

  • Refer urgently to a genetic counselor or hereditary cancer clinic.
  • Take a three-generation pedigree: type of cancer, age at diagnosis, maternal/paternal lineage, bilateral breast cancer, ovarian, pancreatic, prostate, colon, endometrial, and gastric cancers.
  • Offer germline multigene panel testing, not an MMR-only test. The panel should include:
    • Lynch genes: MLH1, MSH2, MSH6, PMS2, EPCAM
    • Breast-cancer predisposition genes: BRCA1, BRCA2, PALB2, TP53, PTEN, CDH1, CHEK2, ATM, and others guided by the pedigree.
  • If a known familial pathogenic variant exists, test specifically for it.
  • Genetic results can affect:
    • choice between conservation and unilateral/bilateral mastectomy,
    • contralateral breast-risk management,
    • ovarian-risk management,
    • screening and cascade testing of relatives.
A prophylactic contralateral mastectomy should not be routine. It is a personalized decision, particularly relevant if a high-penetrance breast-cancer mutation such as BRCA1/2, PALB2, TP53, PTEN, or CDH1 is found.

If Lynch syndrome is confirmed

Arrange syndrome-directed surveillance and gynecologic risk counseling, including colonoscopic surveillance and discussion of endometrial/ovarian risk management. Lynch syndrome is autosomal dominant and involves pathogenic variants in MMR genes, as summarized in Yamada’s Textbook of Gastroenterology.

Practical immediate plan

  1. Core biopsy with ER/PR/HER2 and grade, if not already completed.
  2. Axillary ultrasound and biopsy only if nodes appear suspicious.
  3. CT chest/abdomen/pelvis plus bone scan or PET-CT for T3 staging.
  4. Breast-MDT discussion before surgery.
  5. Start subtype-appropriate neoadjuvant treatment in most cases.
  6. Refer for germline multigene testing and genetic counseling without delaying indicated cancer treatment.
  7. Definitive surgery, radiotherapy, and subtype-directed adjuvant treatment after response/pathology review.
This is an educational management framework, not a substitute for direct oncology care. The missing decisive information is the core-biopsy pathology and ER/PR/HER2 result.
This is a shared conversation. Sign in to Orris to start your own chat.